119 related articles for article (PubMed ID: 1425896)
1. Time-dependent change in the effect of probucol in subjects with elevated cholesterol.
Fujimura A; Ohashi K; Ebihara A
Eur J Clin Pharmacol; 1992; 43(3):299-301. PubMed ID: 1425896
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.
Saku K; Zhang B; Hirata K; Okura Y; Bai H; Liu R; Arakawa K
Eur J Clin Pharmacol; 1993; 44(6):535-9. PubMed ID: 8405008
[TBL] [Abstract][Full Text] [Related]
3. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.
Johansson J; Olsson AG; Bergstrand L; Elinder LS; Nilsson S; Erikson U; Mölgaard J; Holme I; Walldius G
Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1049-56. PubMed ID: 7627695
[TBL] [Abstract][Full Text] [Related]
4. [Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study].
Forti N; Ramires JA
Arq Bras Cardiol; 1991 Sep; 57(3):253-61. PubMed ID: 1824203
[TBL] [Abstract][Full Text] [Related]
5. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
[TBL] [Abstract][Full Text] [Related]
6. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).
Walldius G; Erikson U; Olsson AG; Bergstrand L; Hådell K; Johansson J; Kaijser L; Lassvik C; Mölgaard J; Nilsson S
Am J Cardiol; 1994 Nov; 74(9):875-83. PubMed ID: 7977117
[TBL] [Abstract][Full Text] [Related]
7. Marked decrease in serum HDL cholesterol levels by combined probucol-pravastatin treatment in hypercholesterolemic NIDDM patients.
Ikeda T
Diabetes Care; 1993 May; 16(5):849-50. PubMed ID: 8495635
[No Abstract] [Full Text] [Related]
8. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
[TBL] [Abstract][Full Text] [Related]
9. Mode of hypocholesterolemic action of probucol in animals and man.
Beynen AC
Artery; 1987; 14(2):113-26. PubMed ID: 3551883
[TBL] [Abstract][Full Text] [Related]
10. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV.
Am J Cardiol; 1990 Sep; 66(8):22B-30B. PubMed ID: 2206033
[TBL] [Abstract][Full Text] [Related]
11. Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer.
Bagdade JD; Kaufman D; Ritter MC; Subbaiah PV
Atherosclerosis; 1990 Oct; 84(2-3):145-54. PubMed ID: 2282096
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
[TBL] [Abstract][Full Text] [Related]
13. Probucol: a new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia.
Salel AF; Zelis R; Sodhi HS; Price J; Mason DT
Clin Pharmacol Ther; 1976 Dec; 20(6):690-4. PubMed ID: 186224
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression.
Baldassarre D; Franceschini G; Peruzzotti G; Brusoni B; Sirtori CR
J Cardiovasc Pharmacol; 1997 Dec; 30(6):784-9. PubMed ID: 9436818
[TBL] [Abstract][Full Text] [Related]
15. Probucol in hypercholesterolemia. A double blind study.
Riesen WF; Keller M; Mordasini R
Atherosclerosis; 1980 Jun; 36(2):201-7. PubMed ID: 7406949
[TBL] [Abstract][Full Text] [Related]
16. High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet.
Miida T; Yamaguchi T; Tsuda T; Okada M
Atherosclerosis; 1998 May; 138(1):129-34. PubMed ID: 9678778
[TBL] [Abstract][Full Text] [Related]
17. Clinical and therapeutic use of probucol.
Berg A; Baumstark MW; Frey I; Halle M; Keul J
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S81-4. PubMed ID: 2044650
[TBL] [Abstract][Full Text] [Related]
18. [Behavior of high-density lipoproteins in drug lipid-lowering treatment].
Mordasini R; Riesen W; Oster P; Riva G
Schweiz Med Wochenschr; 1982 Jan; 112(3):95-8. PubMed ID: 7058319
[TBL] [Abstract][Full Text] [Related]
19. Probucol in long-term treatment of hypercholesterolemia.
Strandberg TE; Vanhanen H; Miettinen TA
Gen Pharmacol; 1988; 19(3):317-20. PubMed ID: 3046993
[TBL] [Abstract][Full Text] [Related]
20. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia.
Fellin R; Gasparotto A; Valerio G; Baiocchi MR; Padrini R; Lamon S; Vitale E; Baggio G; Crepaldi G
Atherosclerosis; 1986 Jan; 59(1):47-56. PubMed ID: 3081013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
